These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 25404267

  • 1. [Effects of 17-DMAG on non-small cell lung cancer cell lines A549 and H1975
 being resistant to EGFR-TKI].
    Zhao L, Cao F.
    Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):778-82. PubMed ID: 25404267
    [Abstract] [Full Text] [Related]

  • 2. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
    Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S.
    Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
    [Abstract] [Full Text] [Related]

  • 3. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
    Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S.
    J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
    [Abstract] [Full Text] [Related]

  • 4. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
    Sudo M, Chin TM, Mori S, Doan NB, Said JW, Akashi M, Koeffler HP.
    Cancer Chemother Pharmacol; 2013 May; 71(5):1325-34. PubMed ID: 23515752
    [Abstract] [Full Text] [Related]

  • 5. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
    Wu DW, Chen TC, Huang HS, Lee H.
    Cell Death Dis; 2016 Jun 30; 7(6):e2290. PubMed ID: 27362807
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 30; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 7. P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement.
    Kim HJ, Lee KY, Kim YW, Choi YJ, Lee JE, Choi CM, Baek IJ, Rho JK, Lee JC.
    BMC Cancer; 2015 Jul 29; 15():553. PubMed ID: 26219569
    [Abstract] [Full Text] [Related]

  • 8. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.
    Mol Cancer Res; 2010 Aug 29; 8(8):1142-51. PubMed ID: 20647329
    [Abstract] [Full Text] [Related]

  • 9. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov 29; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB.
    Cancer Res; 2008 Jan 15; 68(2):589-96. PubMed ID: 18199556
    [Abstract] [Full Text] [Related]

  • 11. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.
    Mol Cancer Ther; 2009 Dec 15; 8(12):3296-306. PubMed ID: 19952121
    [Abstract] [Full Text] [Related]

  • 12. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
    Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu YN, Xiong T, Zhang G, Chen Y.
    Cell Biol Int; 2012 Oct 01; 36(10):893-9. PubMed ID: 22694478
    [Abstract] [Full Text] [Related]

  • 13. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 01; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Jun 01; 9(6):2417-22. PubMed ID: 24682085
    [Abstract] [Full Text] [Related]

  • 15. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 01; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 16. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.
    Adv Med Sci; 2011 Jun 01; 56(2):275-84. PubMed ID: 22037177
    [Abstract] [Full Text] [Related]

  • 17. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 Jun 01; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 18. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 01; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer.
    Xie C, Jin J, Bao X, Zhan WH, Han TY, Gan M, Zhang C, Wang J.
    Oncotarget; 2016 Jan 05; 7(1):610-21. PubMed ID: 26575584
    [Abstract] [Full Text] [Related]

  • 20. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.
    Wong C, Chen S.
    Cancer Res; 2009 Nov 15; 69(22):8670-7. PubMed ID: 19861537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.